- Bayer plans a $2.2B pharmaceutical manufacturing campus on about 200 acres in New Albany, Ohio, creating roughly 600 permanent jobs and 1,500 construction positions.
- The campus will be built in two phases, with drug substance manufacturing launching in 2031 and drug product manufacturing in 2034, after a mid-2027 groundbreaking.
- The project joins a wave of U.S. pharmaceutical manufacturing investment driven by supply-chain concerns, tariffs and national security, and it deepens Ohio’s life sciences cluster.
Bayer plans to invest $2.2B in a pharmaceutical manufacturing campus in New Albany, Ohio, according to Commercial Property Executive. Groundbreaking is scheduled for mid-2027.
The facility is expected to be fully operational in 2034.
Get Smarter about what matters in CRE
Stay ahead of trends in commercial real estate with CRE Daily – the free newsletter delivering everything you need to start your day in just 5-minutes
Two Phases Through 2034
The campus will develop in two phases. First, Bayer plans to launch drug substance manufacturing in 2031.
The company will then launch drug product manufacturing in 2034. Together, the phases should create about 600 permanent jobs and roughly 1,500 construction positions.
Inside the New Albany Business Park
The campus will occupy about 200 acres within the New Albany International Business Park. The 12,000-acre development holds roughly 43 million square feet of commercial space.
The site sits south of Route 161 near Beach Road along Ganton Parkway. Nearby companies include pharmaceutical firms American Regent, Amgen and Pharmavite.
Part of a $7B U.S. Push
The Ohio project follows about $7B in Bayer pharmaceutical R&D and manufacturing investment in the U.S. over the past five years.
Meanwhile, the company operates a 46-acre biotech campus in Berkeley, Calif. The campus employs about 1,000 people.
Bayer also completed a $44M expansion of its Myerstown, Pa., facility in 2025.
Why It Matters
The investment reflects broader momentum toward U.S.-based drug production. Supply-chain concerns, tariffs, national security and demand for blockbuster drugs are driving that trend.
Moreover, large manufacturing campuses like this one concentrate land, power and skilled labor in a single market.
Ohio is attracting similar projects. For example, Resilience has a $100M facility planned in Blue Ash. Meanwhile, Eli Lilly’s $6.5B Generation Park groundbreaking shows how large these commitments have grown elsewhere.
What’s Next
With groundbreaking more than eight months away, watch for site preparation, utility commitments and contractor selection.
In addition, the 2031 and 2034 milestones give the project a long runway. The cluster of drugmakers already in New Albany could also attract suppliers and logistics users.
